Altimmune, Inc.

Analysis for Ticker: ALT

Altimmune Inc is a business focused on developing peptide-based therapies for obesity and metabolic dysfunction-associated steatohepatitis but generates 0$ from selling any medical products. The shocking reality is that the company operates as a specialized machine designed to burn cash and print new shares just to keep its doors open. By 12/2024, it had lost 95$ million and built up an accumulated deficit of over 649$ million. The math is a disaster because the business survives by constantly selling new pieces of itself, making the pieces that investors already own worth less over time. It is like owning a slice of a pizza where the chef keeps adding more slices to the same pie for new customers, which makes your slice smaller and smaller every single day. The mechanism of survival began with a cycle of high-interest debt and aggressive selling of equity. In 02/2025, the company used two banks, Piper Sandler and Stifel, to sell 18,5 million shares and extract 81,9$ million from the public. When the money ran low, they turned to Hercules Capital in 05/2025 to borrow 15$ million at a very high 14,4% effective interest rate. This loan is dangerous because Hercules Capital now owns a claim on all the assets of the company if the interest and bills are not paid. By 11/2025, the company was burning through cash so fast they had to borrow another 20$ million at an interest rate of at least 9,7%. They also hired Leerink Partners to sell up to 200$ million more in shares, giving the bank 3% of all the money they managed to collect. Between 09/2025 and 12/2025, they sold 13,5 million new shares to pull 54,6$ million from investors.